31 August 2009
Statins and amiodarone improve freedom from recurrence of atrial fibrillation after successful cardioversion
Franjo NajiABCDEF, David SuranBCF, Vojko KanicAG, Damijan VokacDF, Miso SabovicADEMed Sci Monit 2009; 15(9): CR494-498 :: ID: 878181
Abstract
Background
Amiodarone is effective in preventing atrial fibrillation (AF). Recently, the possible antiarrhythmic effects of statins have been revealed. We hypothesized that statins added to amiodarone may reduce the recurrence rate of AF after successful electrical cardioversion (EC).
Material and Method
The retrospective analysis included 198 consecutive patients (63+/-10 years; 56% men) with persistent AF (lasting at least one month, average 5.8+/-7.6 months) who underwent successful EC. All patients were put on long-time treatment with amiodarone according to standard protocol prior to EC; 50 patients (25%) also received statin therapy. AF recurrence was recorded in the following two years.
Results
Recurrence of AF occurred less frequently in patients receiving statins and amiodarone than in those receiving amiodarone only (24 (48.0%) vs. 95 (64.1%) patients). The mean AF-free period was significantly prolonged in the statin-amiodarone group (513+/-38 days vs. 374+/-25 days, log rank test P<0.02). Cox univariate analysis showed that treatment with statins and the duration of AF before EC were significant predictors for AF recurrence. After adjustment for other potential confounders, statin therapy proved to be a statistically significant predictor of sinus rhythm maintenance (adjusted OR 0.60, 95% CI 0.38 to 0.93, P=0.02).
Conclusions
Our study shows that adding statins to amiodarone significantly decreases the recurrence rate of AF after successful EC in patients with persistent AF. Our findings urge for prospective randomized studies to be performed in order to confirm these results and elucidate the role of statins in AF prevention.
Keywords: Recurrence - prevention & control, Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use, Electric Countershock, Atrial Fibrillation - therapy, Anti-Arrhythmia Agents - therapeutic use, Amiodarone - therapeutic use
Editorial
01 March 2024 : Editorial
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-ThalassemiaDOI: 10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
In Press
21 Feb 2024 : Clinical Research
Potential Value of HSP90α in Prognosis of Triple-Negative Breast CancerMed Sci Monit In Press; DOI: 10.12659/MSM.943049
22 Feb 2024 : Review article
Differentiation of Native Vertebral Osteomyelitis: A Comprehensive Review of Imaging Techniques and Future ...Med Sci Monit In Press; DOI: 10.12659/MSM.943168
23 Feb 2024 : Clinical Research
A Study of 60 Patients with Low Back Pain to Compare Outcomes Following Magnetotherapy, Ultrasound, Laser, ...Med Sci Monit In Press; DOI: 10.12659/MSM.943732
26 Feb 2024 : Clinical Research
Predictive Value of Combined HbA1c and Neutrophil-to-Lymphocyte Ratio for Diabetic Peripheral Neuropathy in...Med Sci Monit In Press; DOI: 10.12659/MSM.942509
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952